Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: Technical recommendations

Riccardo Lencioni, Camillo Aliberti, Thierry De Baere, Ricardo Garcia-Monaco, Govindarajan Narayanan, Elizabeth O'Grady, William S. Rilling, Duncan Walker, Robert C.G. Martin

    Research output: Contribution to journalArticlepeer-review

    51 Citations (Scopus)

    Abstract

    Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.

    Original languageEnglish
    Pages (from-to)365-369
    Number of pages5
    JournalJournal of Vascular and Interventional Radiology
    Volume25
    Issue number3
    DOIs
    Publication statusPublished - 5 Mar 2014

    Cite this